Title:
TRIPLE COMBINATION THERAPY, COMPRISING GANETESPIB, A TAXANE AND AN ANTIBODY, FOR USE IN THE TREATMENT OF HER2 POSITIVE BREAST CANCER
Document Type and Number:
WIPO Patent Application WO/2016/094341
Kind Code:
A8
Abstract:
Disclosed herein is a combination therapy comprising ganetespib, a taxane, and a monoclonal antibody that interferes with the HER2/neu receptor, pharmaceutical compositions thereof, and methods for use, such as to treat humans with HER2-positive breast cancer (BC).
Inventors:
PROIA DAVID (US)
Application Number:
PCT/US2015/064379
Publication Date:
September 15, 2016
Filing Date:
December 08, 2015
Export Citation:
Assignee:
SYNTA PHARMACEUTICALS CORP (US)
International Classes:
A61K39/395; A61K31/337; A61K31/4196; A61K45/06; A61P35/00
Attorney, Agent or Firm:
DAVIS, Steven, G. et al. (LLP265 Franklin Stree, Boston MA, US)
Download PDF:
Previous Patent: PROCESSES FOR THE RECOVERY OF AROMATIC HYDROCARBONS FROM VAPOR GAS STREAMS
Next Patent: LIPOCATIONIC POLYMERS AND USES THEREOF
Next Patent: LIPOCATIONIC POLYMERS AND USES THEREOF